Welcome to our dedicated page for Prestige Consumer Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consumer Healthcare stock.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading provider of over-the-counter (OTC) healthcare products, serving consumers across North America and globally in markets such as Australia, New Zealand, and Asia. The company boasts a diverse portfolio of trusted brands that include household names like Clear Eyes, DenTek, Summer's Eve, Monistat, BC, Goody's, and Dramamine, among others. With a focus on product innovation and quality, Prestige Consumer Healthcare aims to enhance the lives of its customers worldwide.
Founded on the principles of trust and reliability, Prestige Consumer Healthcare is recognized as the largest independent provider of OTC healthcare products in North America. The company's success is attributed to its ability to remain agile while maintaining detailed attention to its extensive range of product offerings. This is reflected in the company's consistent efforts to improve and create products that align with the ever-evolving needs of consumers and their families.
Recent achievements for Prestige Consumer Healthcare include strong financial performances, as evidenced by their second quarter fiscal 2024 results. The company reported revenues of $286.3 million and a net income of $53.6 million, highlighting a robust growth in earnings per share. This was driven by the diverse and leading portfolio of brands, along with broad distribution and a solid financial model. Strong performances in categories such as Cough & Cold and Ear & Eye Care contributed significantly to these results.
In terms of financial health, Prestige Consumer Healthcare continues to demonstrate strong cash flow generation. For the second quarter of fiscal 2024, the company reported net cash provided by operating activities at $62.5 million and a non-GAAP free cash flow of $59.5 million. Debt reduction and disciplined capital deployment remain key priorities, with the company reducing its net debt to approximately $1.2 billion and achieving a leverage ratio of 3.0x.
Partnerships and global reach are also integral to Prestige Consumer Healthcare's strategy. The company generates around 85% of its total revenue from North America, with the remaining sales coming from international markets. Key brands such as Hydralyte in Australia and niche consumer health products in other regions underscore the company's global presence and commitment to meeting diverse healthcare needs.
Looking ahead, Prestige Consumer Healthcare is optimistic about its growth prospects, reaffirming its fiscal 2024 outlook with expectations of continued sales and earnings growth. The company remains well-positioned to create long-term shareholder value through stable organic growth and strategic capital allocation.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is set to release its fiscal 2023 fourth quarter and year-end earnings on May 4, 2023, before market opening. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss these results. Investors can access the live webcast through the company's Investor Relations page or register for a phone call. A replay of the call will be available for a week post-event. Prestige Consumer Healthcare offers a diverse range of consumer healthcare products including Monistat®, BC®, Dramamine®, and many others, serving markets across the U.S., Canada, Australia, and beyond.
Prestige Consumer Healthcare (PBH) reported Q3 fiscal 2023 revenues of $275.5 million, a 0.4% increase from the previous year, with 1.8% growth excluding currency effects. Net income rose to $52.0 million, yielding diluted EPS of $1.04, up 5.1%. For the first nine months, revenues reached $841.9 million, a 2.7% increase year-over-year. The International OTC segment saw record revenues, growing 15.0% to $38.6 million. Management anticipates fiscal 2023 revenues between $1,120 and $1,122 million, projecting over 3% growth.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will participate in the 2023 ICR Conference, hosting a fireside chat on January 10, 2023, at 2:30 p.m. ET. Interested parties can access the live webcast through the company's website under the 'Investors' section. Prestige Consumer Healthcare distributes various well-known consumer healthcare products including Monistat®, Summer’s Eve®, and Dramamine®. The firm's diverse portfolio serves retail markets in the U.S., Canada, Australia, and other international locations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced that it will release its fiscal 2023 third quarter earnings on February 2, 2023, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. ET on the same day. Investors can join the call via a live Internet webcast or by phone after registering. A replay of the call will be available for one week afterward. This earnings report is pivotal for stakeholders to gauge the company’s financial health and performance metrics.
Prestige Consumer Healthcare (NYSE:PBH) reported Q2 fiscal 2023 revenue of $289.3 million, a 4.7% increase over the previous year, and earnings per share (EPS) of $1.02, surpassing expectations. The company reduced its debt by $35 million, achieving a leverage ratio of 3.7x. For the first half of fiscal 2023, revenue reached $566.3 million, up 3.8%. The company reaffirmed its fiscal 2023 revenue outlook of $1,120 to $1,130 million and EPS guidance of $4.18 to $4.23, amidst ongoing supply chain challenges.
Prestige Consumer Healthcare (NYSE:PBH) announced its fiscal 2023 Q2 earnings release on November 3, 2022, prior to market opening. The company will conduct a conference call at 8:30 a.m. ET on the same day to discuss the earnings results. Investors can join the live webcast via the Investor Relations page on their website or register for phone participation to receive dial-in details. A replay of the conference call will be available for one week post-event.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will present at the 2022 Barclays Global Consumer Staples Conference on September 8, 2022, at 12:45 p.m. ET. Interested parties can access a live webcast via the company's website in the 'Investors' section. For those unable to attend the live session, a replay will be available afterward.
Prestige Consumer Healthcare offers a diverse range of products including Monistat®, Summer’s Eve®, BC®, and many more, catering to consumers across the U.S., Canada, Australia, and other international markets.
FAQ
What is the current stock price of Prestige Consumer Healthcare (PBH)?
What is the market cap of Prestige Consumer Healthcare (PBH)?
What does Prestige Consumer Healthcare Inc. do?
Where does Prestige Consumer Healthcare generate most of its revenue?
What recent financial results has Prestige Consumer Healthcare reported?
How is Prestige Consumer Healthcare managing its debt?
What are some of the key brands under Prestige Consumer Healthcare?
What is the company's approach to product innovation?
What is the company's outlook for the future?
How does Prestige Consumer Healthcare support its global operations?
What is the company's financial strategy?
How can investors access the company's financial updates?
